381 related articles for article (PubMed ID: 27397043)
21. Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.
Bender C; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
Ann Oncol; 2016 Jul; 27(7):1353-4. PubMed ID: 26951629
[No Abstract] [Full Text] [Related]
22. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
23. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
24. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
25. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
Jang S; Venna S
J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
[No Abstract] [Full Text] [Related]
26. In brief: Brentuximab vedotin (Adcetris) for classical hodgkin's lymphoma.
Med Lett Drugs Ther; 2018 Nov; 60(1559):e185. PubMed ID: 30681659
[No Abstract] [Full Text] [Related]
27. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
Yu Y
Front Med; 2018 Apr; 12(2):229-235. PubMed ID: 29209918
[TBL] [Abstract][Full Text] [Related]
28. Arterial thrombosis and anti-PD-1 blockade.
Boutros C; Scoazec JY; Mateus C; Routier E; Roy S; Robert C
Eur J Cancer; 2018 Mar; 91():164-166. PubMed ID: 29289455
[No Abstract] [Full Text] [Related]
29. PD-1 inhibitors effective in hodgkin lymphoma.
Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882
[No Abstract] [Full Text] [Related]
30. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
Haug V; Behle V; Benoit S; Kneitz H; Schilling B; Goebeler M; Gesierich A
Br J Dermatol; 2018 Oct; 179(4):993-994. PubMed ID: 29758087
[No Abstract] [Full Text] [Related]
31. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.
Singh AK; Porrata LF; Aljitawi O; Lin T; Shune L; Ganguly S; McGuirk JP; Abhyankar S
Bone Marrow Transplant; 2016 Sep; 51(9):1268-70. PubMed ID: 27111048
[No Abstract] [Full Text] [Related]
32. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
Goldstein DA; Bilal U; Prasad V
Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
[No Abstract] [Full Text] [Related]
33. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
Chan TSY; Li J; Loong F; Khong PL; Tse E; Kwong YL
Ann Hematol; 2018 Jan; 97(1):193-196. PubMed ID: 28879531
[No Abstract] [Full Text] [Related]
34. Pembrolizumab in advanced head and neck cancer.
Brower V
Lancet Oncol; 2017 May; 18(5):e248. PubMed ID: 28366274
[No Abstract] [Full Text] [Related]
35. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
36. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
[No Abstract] [Full Text] [Related]
37. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
38. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
Cousin S; Toulmonde M; Kind M; Cazeau AL; Bechade D; Coindre JM; Italiano A
Ann Oncol; 2016 Jun; 27(6):1178-1179. PubMed ID: 27091806
[No Abstract] [Full Text] [Related]
39. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
40. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]